Total Valuation
Pharming Group has a market cap or net worth of €777.50M. The enterprise value is €958.34.
Market Cap€777.50M
Enterprise Value€958.34
Share Statistics
Pharming Group has 707,781,250 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding707,781,250
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Pharming Group’s return on equity (ROE) is 0.01 and return on invested capital (ROIC) is 1.05%.
Return on Equity (ROE)0.01
Return on Assets (ROA)<0.01
Return on Invested Capital (ROIC)1.05%
Return on Capital Employed (ROCE)0.05
Revenue Per Employee924.16K
Profits Per Employee31.57K
Employee Count407
Asset Turnover0.75
Inventory Turnover0.70
Valuation Ratios
The current PE Ratio of Pharming Group is 64.2. Pharming Group’s PEG ratio is -2.78.
PE Ratio64.2
PS Ratio2.74
PB Ratio3.72
Price to Fair Value3.72
Price to FCF20.17
Price to Operating Cash Flow17.68
PEG Ratio-2.78
Income Statement
In the last 12 months, Pharming Group had revenue of 376.13M and earned 2.97M in profits. Earnings per share was <0.01.
Revenue376.13M
Gross Profit330.63M
Operating Income20.88M
Pretax Income12.85M
Net Income2.97M
EBITDA34.78M
Earnings Per Share (EPS)<0.01
Cash Flow
In the last 12 months, operating cash flow was 40.88M and capital expenditures -579.01K, giving a free cash flow of 40.30M billion.
Operating Cash Flow40.88M
Free Cash Flow40.30M
Free Cash Flow per Share0.06
Dividends & Yields
Pharming Group pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.58
52-Week Price Change-8.94%
50-Day Moving Average1.15
200-Day Moving Average1.33
Relative Strength Index (RSI)46.07
Average Volume (3m)11.21K
Important Dates
Pharming Group upcoming earnings date is Nov 5, 2026, Before Open (Confirmed).
Last Earnings DateJul 30, 2026
Next Earnings DateNov 5, 2026
Ex-Dividend Date―
Financial Position
Pharming Group as a current ratio of 2.59, with Debt / Equity ratio of 43.21%
Current Ratio2.59
Quick Ratio2.03
Debt to Market Cap0.10
Net Debt to EBITDA-0.87
Interest Coverage Ratio1.95
Taxes
In the past 12 months, Pharming Group has paid 10.31M in taxes.
Income Tax10.31M
Effective Tax Rate0.80
Enterprise Valuation
Pharming Group EV to EBITDA ratio is 28.80, with an EV/FCF ratio of 19.57.
EV to Sales2.66
EV to EBITDA28.80
EV to Free Cash Flow19.57
EV to Operating Cash Flow19.28
Balance Sheet
Pharming Group has €158.25M in cash and marketable securities with €126.73M in debt, giving a net cash position of €31.52M billion.
Cash & Marketable Securities€158.25M
Total Debt€126.73M
Net Cash€31.52M
Net Cash Per Share€0.04
Tangible Book Value Per Share€0.20
Margins
Gross margin is 88.12%, with operating margin of 5.55%, and net profit margin of 0.79%.
Gross Margin88.12%
Operating Margin5.55%
Pretax Margin3.42%
Net Profit Margin0.79%
EBITDA Margin9.25%
EBIT Margin5.78%
Analyst Forecast
The average price target for Pharming Group is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast6.65%
EPS Growth Forecast―